Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3806-3810

  Arora, Sonia ^a   Yang, Jin Ming ^a,b   Hait, William N ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ELONGATION FACTOR 2; ELONGATION FACTOR 2 KINASE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN); UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CLINICAL PATHWAY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME METABOLISM; ENZYME STABILITY; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; PRIORITY JOURNAL; REGULATORY MECHANISM; TURNOVER TIME; UBIQUITIN PROTEASOME PATHWAY;

CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL LINE, TUMOR; ENZYME STABILITY; FEMALE; GLIOBLASTOMA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; OVARIAN NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 18144425142     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4036     Document Type: Article

References (39)

1. Ryazanov AG, Ward MD, Mendola CE, et al. Identification of a new class of protein kinases represented by eukaryotic elongation factor-2 kinase. Proc Natl Acad Sci U S A 1997;94:4884-9.
2. Redpath NT, Price NT, Proud CG. Cloning and expression of cDNA encoding protein synthesis elongation factor-2 kinase. J Biol Chem 1996;271:17547-54.
3. Cote GP, Luo X, Murphy MB, Egelhoff TT. Mapping of the novel protein kinase catalytic domain of Dictyostelium myosin II heavy chain kinase A. J Biol Chem 1997;272:6846-9.
4. Clancy CE, Mendoza MG, Naismith TV, Kolman MF, Egelholl TT. Identification of a protein kinase from Dictyostelium with homology to the novel catalytic domain of myosin heavy chain kinase A. J Biol Chem 1997;272:11812-5.
5. Riazanova LV, Pavur KS, Petrov AN, Dorovkov MV, Riazonov AG. Novel type of signaling molecules: protein kinases covalently linked to ion channels. Mol Biol (Mosk) 2001;35:321-32.
6. Ryazanov AG, Shestakova EA, Natapov PG. Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation. Nature 1988;334:170-3.
7. Ryazanov AG, Rudkin BB, Spirin AS. Regulation of protein synthesis at the elongation stage. New insights into the control of gene expression in eukaryotes. FEBS Lett 1991;285:170-5.
8. 2+ transients. J Biol Chem 1987;262:9785-92.
9. 2+/calmodulin-dependent phosphorylation of the 100-kDa protein and membrane fusion of chick embryonic myoblasts. Dev Biol 1994;165:178-84.
10. Severinov KV, Melnikova EG, Ryazanov AG. Downregulation of the translation elongation factor 2 kinase in Xenopus laevis oocytes at the final stages of oogenesis. New Biol 1990;2:887-93.
11. Celis JE, Madsen P, Ryazanov AG. Increased phosphorylation of elongation factor 2 during mitosis in transformed human amnion cells correlates with a decreased rate of protein synthesis. Proc Natl Acad Sci U S A 1990;87:4231-5.
12. End D, Hanson M, Hashimoto S, Guroff G. Inhibition of the phosphorylation of a 1000,000-dalton soluble protein in whole cells and cell-free extracts of PC12 pheochromocytoma cells following treatment with nerve growth factor. J Biol Chem 1982;257:9223-5.
13. Koizumi S, Ryazanov A, Hama T, Chen HC, Guroff G. Identification of Nsp100 as elongation factor 2 (EF-2). FEBS Lett 1989;253:55-8.
14. Brady MJ, Nairn AC, Wagner JA, Palfrey HC. Nerve growth factor-induced down-regulation of calmodulin-dependent protein kinase III in PC12 cells involves cyclic AMP-dependent protein kinase. J Neurochem 1990;54:1034-9.
15. Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, Hait WN. Activity and regulation by growth factors of carmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer 1999;79:59-64.
16. Bagaglio DM, Hait WN. Role of calmodulin-dependent phosphorylation of elongation factor 2 in the proliferation of rat glial cells. Cell Growth Differ 1994;5:1403-8.
17. Marin P, Nastiuk KL, Daniel N, et al. Glutamate-dependent phosphorylation of elongation factor-2 and inhibition of protein synthesis in neurons. J Neurosci 1997;17:3445-54.
18. Scheetz AJ, Naim AC, Constantine-Paton M. NMDA receptor-mediated control of protein synthesis at developing synapses. Nat Neurosci 2000;3:211-6.
19. Scheetz AJ, Naim AC, Constantine-Paton M. N-Methyl-D-aspartate receptor activation and visual activity induce elongation factor-2 phosphorylation in amphibian tecta: a role for N-methyl-D-aspartate receptors in controlling protein synthesis. Proc Natl Acad Sci USA 1997;94:14770-5.
20. Bagaglio DM, Cheng EH, Gorelick FS, Mitsui K, Naim AC, Hait WN. Phosphorylation of elongation factor 2 in normal and malignant rat glial cells. Cancer Res 1993;53:2260-4.
21. Parmer TG, Ward MD, Hait WN. Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ 1997;8:327-34.
22. Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, Hait WN. Disruption of the EF-2 kinase/Ilsp 90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res 2001;61:4010-6.
23. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays 2000;22:442-51.
24. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002;3:20-6.
25. Pickart CM. Ubiquitin enters the new millennium. Mol Cell 2001;8:499-504.
26. Hershko A, Ciechanover A, Varshavsky A. Basic Medical Research Award. The ubiquitin system. Nat Med 2000;6:1073-81.
27. Fang S, Weissman AM. A field guide to ubiquitylation. Cell Mol Life Sci 2004;61:1546-61.
28. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001;2:169-78.
29. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003;302:1972-5.
30. Mitchell BS. The proteasome - an emerging therapeutic target in cancer. N Engl J Med 2003;348:2597-8.
31. Arora S, Yang JM, Kinzy TG, et al. Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res 2003;63:6894-9.
32. Browne GJ, Proud CG. Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 2002;269:5360-8.
33. Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 2004;313:429-36.
34. Knebel A, Haydon CE, Morrice N, Cohen P. Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways. Biochem J 2002;367:525-32.
35. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 2001;20:4370-9.
36. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
37. Ciechanover A. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 2003;31:474-81.
38. Hait WN, Ward MD, Trakht IN, Ryazanov AG. Elongation factor-2 kinase immunological evidence for the existence of tissue-specific isoforms. FEBS Lett 1996;397:55-60.
39. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283-90.